Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Angiogenesis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DLL4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DLL4 ECD-Fc Fusion Protein (High purity >95%, Endotoxin <1EU/ug, HEK293 expressed with native glycosylation, Sequence Verified). | View DLL4 Products |
| Gene Delivery | DLL4 Promise-ORF / Lentivirus (Full-length ORF for stable cell lines, Endotoxin controlled). | View DLL4 Products |
| Benchmark Ab | Anti-DLL4 (Sequences of Enoticumab and Demcizumab) Recombinant positive controls. | View DLL4 Products |
| Validator | DLL4 siRNA Set (For knockdown verification, Sequence Verified). | View DLL4 Products |
| Pathway Partner | VEGFA (Synergistic angiogenesis target for combination studies). | View VEGFA Products |
| Receptor Target | NOTCH1 (Primary receptor for DLL4 signaling validation). | View NOTCH1 Products |
| Paralog | DLL1 (Structural homolog for selectivity counter-screening). | View DLL1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog DLL4 proteins available with >95% purity; Sequence Verified by Mass Spec. |
| Subfamily Selectivity (vs DLL1/DLL3) | DLL1/DLL3 homolog panel proteins strictly verified by mass spec for off-target screening. |
| Glycosylation-dependent Activity | HEK293 expressed proteins preserving native N-glycosylation sites (Asn-67, Asn-159) for accurate Notch binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Enoticumab/Demcizumab biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks in reporter assays. |
Live DLL4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DLL4 therapeutics is intensifying, with major players shifting focus from traditional monospecific antibodies to bispecific formats targeting DLL4/VEGF co-inhibition. Following the Phase II discontinuation of first-generation mAbs (e.g., Enoticumab, Demcizumab) due to vascular toxicity concerns, the next wave of R&D is targeting epitope-engineered antibodies with improved therapeutic windows and ADC conjugates for tumor-specific payload delivery. The current pipeline emphasizes optimized safety profiles to mitigate Notch-pathway-related toxicities while maximizing anti-tumor angiogenesis efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibody | AbbVie, Mereo BioPharma, Sanofi, Akeso Biopharma | Solid Tumors (Ovarian, Gastric, HCC, CRC) | Dual-binding Validation (Need Cross-reactive Abs against DLL4 and VEGF) |
| Monoclonal Antibody | Regeneron (Enoticumab), OncoMed (Demcizumab) | Colorectal Cancer | Epitope Mapping (Need Cyno/Mouse Cross-reactive Abs) |
| ADC | Biotechs (Undisclosed) | Pancreatic, Glioblastoma | Internalization Assay (Need high-purity ECD-Fc for binding/internalization kinetics) |
| Decoy Receptor | Academic Consortia | Vascular Proliferation | Affinity Maturation (Need SPR-validated Notch1-DLL4 binding inhibition) |
| Recombinant Protein | Multiple Biotechs | Vascular Diseases | Reporter Assays (Need Lentivirus for Cell Lines) |